Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | CHIEF BUSINESS OFFICER | August 04, 2026 | August 06, 2026 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Chief Business Officer | February 01, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-04 · Exercise / conversion · Acquired 50,366 · Balance 50,366 Row 2 · 2026-08-04 · Exercise / conversion · Acquired 40,250 · Balance 90,616 Row 3 · 2026-08-04 · Sale · Disposed 90,616 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.92 · Expires 2034-08-08 | Direct | 78,542 |
Reported balance
After 2026-08-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-04 · Exercise / conversion · Disposed 50,366 · Balance 78,542 F3: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2035-07-28 | Direct | 120,750 |
Reported balance
After 2026-08-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-04 · Exercise / conversion · Disposed 40,250 · Balance 120,750 F4: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
F2: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
F4: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
Olema Pharmaceuticals, Inc.
Report date February 01, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2033-01-31 | Direct | 150,000 |
Reported balance
After 2023-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 150,000 · Balance 150,000 F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 22:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,250 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001831215-26-000005 · form4-08062026_100833.xml · derivative · entry 5 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,750 Underlying: Common Stock · 40,250 shares Expires 2035-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 50,366 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001831215-26-000005 · form4-08062026_100833.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,542 Underlying: Common Stock · 50,366 shares Expires 2034-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:30 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 90,616 | $25.09 | $2,273,555.44 |
DisclosureSEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2 · price: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 40,250 | $10.60 | $426,650.00 |
DisclosureSEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 22:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 50,366 | $12.92 | $650,728.72 |
DisclosureSEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0001831215-26-000004 · form4-07272026_040712.xml · derivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2036-07-22 F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001831215-26-000004 · form4-07272026_040712.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,250 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 21:38 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,092 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001831215-26-000002 · form4-07092026_090734.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,908 Underlying: Common Stock · 1,092 shares Expires 2034-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 21:38 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 1,092 | $25.00 | $27,300.00 |
DisclosureSEC source: 0001831215-26-000002 · form4-07092026_090734.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 21:38 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 1,092 | $12.92 | $14,108.64 |
DisclosureSEC source: 0001831215-26-000002 · form4-07092026_090734.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 22:55 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 161,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001415889-25-020785 · form4-07312025_100734.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 161,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 21:51 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 130,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001415889-24-021236 · form4-08132024_090819.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 02:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $23.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004704 · form4-02222024_020242.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-02-19 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on February 12, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001209191-23-006285 · doc4.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:45 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,253 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-22-002936 · form4-03142022_010315.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,785 Underlying: Common Stock · 5,253 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:45 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,253 | $4.75 | $24,951.75 |
DisclosureSEC source: 0001415889-22-002936 · form4-03142022_010315.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:45 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,253 | $2.06 | $10,842.19 |
DisclosureSEC source: 0001415889-22-002936 · form4-03142022_010315.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-22-001314 · form4-02142022_020227.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,038 Underlying: Common Stock · 5,251 shares Expires 2030-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Disposition to issuerCommon Stock | 5,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-001314 · form4-02142022_020227.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $5.46, and the range of prices were between $5.14 and $5.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:18 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-22-001314 · form4-02142022_020227.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:07 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 133,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001415889-22-001058 · form4-02032022_040207.xml · derivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,000 Underlying: Common Stock · 133,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 01:21 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-22-000480 · form4-01112022_050141.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,289 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 01:21 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,251 | $6.85 | $35,969.35 |
DisclosureSEC source: 0001415889-22-000480 · form4-01112022_050141.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $6.85, and the range of prices were between $6.60 and $7.22. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 01:21 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-22-000480 · form4-01112022_050141.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-005866 · form4-12142021_011252.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,540 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,251 | $10.39 | $54,557.89 |
DisclosureSEC source: 0001415889-21-005866 · form4-12142021_011252.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,458 F2 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $10.39, and the range of prices were between $10.18 and $11.11. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:25 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-005866 · form4-12142021_011252.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 668 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,417 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005174 · form4-11122021_021156.xml · derivative · entry 5 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,253 Underlying: Common Stock · 22,417 shares Expires 2030-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One thirty-sixth of the remaining number of shares subject to the option vest on a monthly basis, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-005174 · form4-11122021_021156.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,791 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 27,668 | $26.88 | $743,715.84 |
DisclosureSEC source: 0001415889-21-005174 · form4-11122021_021156.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: T he weighted average sale price for the transaction reported was $26.88, and the range of prices was between $26.56 and $27.32. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 22,417 | $19.00 | $425,923.00 |
DisclosureSEC source: 0001415889-21-005174 · form4-11122021_021156.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 22:15 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-005174 · form4-11122021_021156.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-004829 · form4-10122021_031058.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,042 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,146 | $28.19 | $88,685.74 |
DisclosureSEC source: 0001415889-21-004829 · form4-10122021_031058.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $28.19, and the range of prices were between $27.88 and $28.62. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,105 | $27.47 | $57,824.35 |
DisclosureSEC source: 0001415889-21-004829 · form4-10122021_031058.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,936 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $27.47, and the range of prices were between $26.88 and $27.87. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 11, 2021 Filed Oct 12, 2021 22:53 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-004829 · form4-10122021_031058.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 00:07 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-004370 · form4-09132021_050950.xml · derivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,293 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 00:07 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,251 | $29.38 | $154,274.38 |
DisclosureSEC source: 0001415889-21-004370 · form4-09132021_050950.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $29.38, and the range of prices were between $29.01 and $29.59. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 00:07 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-004370 · form4-09132021_050950.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-003861 · form4-08112021_030846.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,544 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 60 | $26.17 | $1,570.20 |
DisclosureSEC source: 0001415889-21-003861 · form4-08112021_030846.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 5,191 | $25.70 | $133,408.70 |
DisclosureSEC source: 0001415889-21-003861 · form4-08112021_030846.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $25.70, and the range of prices were between $25.11 and $26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 22:05 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-003861 · form4-08112021_030846.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:27 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-003598 · form4-07132021_030746.xml · derivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,795 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:27 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 1,392 | $27.00 | $37,584.00 |
DisclosureSEC source: 0001415889-21-003598 · form4-07132021_030746.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $27.00, and the range of prices were between $26.80 and $27.16. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:27 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 3,859 | $26.33 | $101,607.47 |
DisclosureSEC source: 0001415889-21-003598 · form4-07132021_030746.xml · nonDerivative · entry 2 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,182 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The weighted average sale price for the transaction reported was $26.33, and the range of prices were between $25.74 and $26.72. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 12, 2021 Filed Jul 13, 2021 22:27 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 5,251 | $2.06 | $10,838.06 |
DisclosureSEC source: 0001415889-21-003598 · form4-07132021_030746.xml · nonDerivative · entry 1 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (right to buy) · Derivative | 5,251 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001415889-21-002957 · form4-06112021_010653.xml · derivative · entry 5 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,046 Underlying: Common Stock · 5,251 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,787 | $29.97 | $83,526.39 |
DisclosureSEC source: 0001415889-21-002957 · form4-06112021_010653.xml · nonDerivative · entry 4 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The weighted average sale price for the transaction reported was $29.97, and the range of prices were between $29.82 and $30.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | SaleCommon Stock | 2,164 | $29.60 | $64,054.40 |
DisclosureSEC source: 0001415889-21-002957 · form4-06112021_010653.xml · nonDerivative · entry 3 Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,577 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The weighted average sale price for the transaction reported was $29.60, and the range of prices were between $28.81 and $29.80. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.